As Global Head of Product Development at Sandoz, a Novartis division, Dr. Deshmukh leads a team of 1000+ associates carrying out integrated product development for generic and differentiated products across the world. He oversees the strategy, performance and capability building for R&D teams including clinical, medical, technical and regulatory domains. Dr. Deshmukh also oversees the product investment strategy as a member of the Sandoz Executive Committee. Technology development and building world-class teams has been Dr. Deshmukh’spassion throughout his life. In his 20 years in pharmaceutical R&D he has contributed over fifty lectures/publications, patents and brought to market multiple billion dollar products. He helped pioneer Quality by Design as part of the US FDA’s pilot program for the first regulatory approval for a QbDparenteral drug. This year, his team helped Sandoz become the first multinational pharmaceutical company to get approval for a Quality Certificate of Excellence (QCE) generic in China. Prior to joining Novartis in 2016, Dr. Deshmukh was Senior Vice President of R&D at Sun Pharma where he led efforts in generic and differentiated generics (505-b2) product development and pipeline strategy with teams based in India, EU and the US. Previously he held leadership roles at Pfizer/Wyeth including Head of US Materials Science and Senior Director for Technology Operations. His training includes a Ph.D. as Aristech Foundation Fellow from the University of Pittsburgh, USA. He also holds an MBA with honors from the Wharton School, University of Pennsylvania, USA.